Johan Engdahl

Johan Engdahl

Professor/Senior Consultant
Mobile phone: 073-7593374
Visiting address: Entrévägen 2, 18257 Danderyd
Postal address: D1 Kliniska vetenskaper, Danderyds sjukhus, D1 Kardiologi Arytmi, 171 77 Stockholm
Part of:

About me

  • I hold a position as a professor of Cardiology at the Department of Clinical Sciences, Karolinska Institutet, and as a senior consultant, Department of Cardiology at  the same hospital. Our research group is dedicated to improve detection, monitoring and treatment in patients with atrial fibrillation, partly by studying ECG screening and alternative ways of detecting patients with atrial fibrillation. 

Research

  • The majority of our projects are clinical trials, many of them with hard clinical endpoints. One of the landmark studies on atrial fibrillation screening, STROKESTOP (NCT01593553), was performed by our group. The biomarker-enhanced STROKESTOP II (NCT02743416) will report the primary endpoint during 2024. A randomised clinical trial on AF detection post stroke (AF SPICE, NCT05134454) is recruiting from 30 stroke units in Sweden and will report its primary endpoint in 2028. Further projects include developement and implementation of smartphone PPG heart rhythm diagnosis (SMARTBEATS, NCT04300270), digital, siteless and risk prediction model-enhanced atrial fibrillation screening in high-risk groups (CONSIDERING-AF, NCT05838781), the relation between excessive supraventricular activity and atrial fibrillation (ESA AF, NCT04593498) and a longitudinal study on progression of atrial fibrllation in the young (PRAY, NCT05080712).

Articles

All other publications

Selected grants

  • Swedish Research Council
    1 January 2024 - 31 December 2027
    The purpose of the trial is to study the prognostic impact of ECG investigation after stroke or Transient Ischemic Attack (TIA).The aim is to investigate if extended ECG screening after stroke or TIA as compared to standard ECG screening for atrial fibrillation reduces the occurrence of the primary composite endpoint of stroke, death and intracranial bleeding.P: Patients aged ≥70 years and admitted for ischemic stroke/TIA in Swedish stroke units. I: Extended long-term ECG-recording of 14 + 14 days duration using patch ECG, read in a core facility. Oral anticoagulation treatment will be suggested to all cases detected with atrial fibrillation in intervention and control arm unless contraindicated.C: Standard ECG recording of 48 hO: Primary outcome is a composite of stroke, all-cause mortality and intracerebral bleeding. Secondary and exploratory oucomes include the individual components of the primary endpoint, intracranial bleedning, myocardial infarction, major bleeding and pacemaker implantation. Endpoint and majority of baseline data will be collected from Swedish health care registers, mainly Riksstroke but also inpatient, drug prescription and cause of death register. Sample size is estimated at 2700. Pilot study commenced ni 2022, main trial is planned to recruit 2023-2026 and follow-up 2027-2028.Given a positive result, the study will give evidence to an investigation and treatment that will improve prognosis in a large group of patients with very poor prognosis.

Grants

  • Swedish Heart-Lung Foundation
    1 January 2024 - 31 December 2025
    Bakgrund: Atrial fibrillation (AF) is the most common clinical arrhythmia affecting more than 3 % of the adult population. For symptomatic patients, treatments to achieve normal sinus rhythm such as cardioversion or ablation are options. Cardioversion is a resource-demanding procedure requiring brief hospitalisation and anesthesist assitance. One of the unsolved challenges in planned AF cardioversion is the lack of information on the patient´s heart rhythm. During the waiting time for planned AF cardioversion, approximately 25 percent of the patients convert spontaneously to sinus rhythm, often without the patient noticing. In these cases, cardioversion must be cancelled with short notice, often with no possibility to call in a replacement from the patient waiting list. Målsättning: The purpose of the clinical investigation is to study if peri-cardioversion recordings of heart rhythm and daily reminders of oral anticoagulation treatment is superior to standard care in reducing the number of late (same day) cancellations for elective cardioversion for atrial fibrillation. Arbetsplan: Randomized, single center clinical trial with open allocation and open endpoint. Participants will be randomised 1:1 to compare active heart rhythm monitoring 2 times daily starting 2-4 weeks before scheduled cardioversion (intervention) to standard treatment which inferes no monitoring (control). Heart rhythm monitoring in intervention arm will use a smartphone-based pulsepletysmographic (PPG) device with the backup of a one-lead ECG device attached to the smartphone. The PPG device has been subject to extensive validation and the project is approved by the medical products agency. All participants still in atrial fibrillation at the scheduled cardioversion will record their heart rhythm twice daily for four weeks post cardioversion. We will establish feasibility and safety of the intervention, and the efficacy of detecting spontaneous cardioversion upfront the scheduled cardioversion procedure. Betydelse:The availability of ambulatory heart rhythm recording devices is very limited in clinical practice and not used in the current setting peri-cardioversion. Since symptoms are unreliable in AF, spontaneous cardioversion to normal rhythm is not always noted by the patient. Information on heart rhtyhm and symptoms are crucial berfore and after AF cardioversion but currently with very limited availability, making treatment decisions misguided.
  • Swedish Heart-Lung Foundation
    1 January 2024 - 31 December 2025
    Bakgrund: Stroke är en av de ledande orsakerna till död, och en vanlig orsak till permanent funktionsnedsättning hos vuxna. Förmaksflimmer (FF) är den vanligast rubbningen av hjärtrytmen och förekomsten av FF ökar kraftigt med ökande ålder. FF är associerat med en flerfaldigt ökad risk för stroke hos individer med riskfaktorer, och FF kan i upp till en tredjedel av fallen föreligga utan symptom. Störst risk för stroke vid FF finns hos de individer som redan drabbats av stroke, därför anses det högt prioriterat att undersöka hjärtrytmen i denna grupp, då fynd av FF innebär en förändring av den blodförtunnande behandlingen med åtföljande minskningen av strokerisken. Antikoagulantia-behandling minskar risken för stroke med 70% vid FF. Det finns ännu inga studier som visar på om det finns en prognostisk nytta av att undersöka förekomst av FF efter stroke. Trots denna kunskapslucka så ges screening av FF efter stroke hög prioritet i de flesta nationella och internationella rekommendationer, men innehållet och styrkan på rekommendationerna varierar stort. Vidare så används idag också stora kliniska resurser på dessa EKG-utredningar trots att det saknas evidens för den eventuella nyttan. Denna kunskapslucka leder till osäkerhet och variationer i rekommendationer för EKG-utredning efter stroke och ojämlik utredning och vård. Målsättning: Syftet med projektet är att studera om utökad EKG-utredning på patienter som haft ischemisk stroke eller TIA leder till reduktion av hårda kliniska utfallsmått som stroke, död och intracerebral blödning genom utökad detektion av FF och utökad andel blodförtunnande behandling. Arbetsplan:Randomiserad Registerbaserad studie (RRCT) av patienter minst 70 år gamla som vårdas inneliggande för ischemisk stroke eller TIA. Randomisering till standardutredning (EKG under 1-2 dygn) eller utökad utredning (EKG under 14 dygn vid 2 tillfällen) och insättande av antikoagulantia i de fall nytt FF diagnosticeras i båda grupperna. Uppföljning av komposit utfall i form av stroke, död och intracerebral blödning under minst tre år. Nära samarbete med Riksstroke. Betydelse:Projektets utfall kommer att få stor betydelse för framtida utredning efter stroke och även för patienter som drabbas av stroke och TIA, en stor grupp patienter som idag har mycket dålig prognos. Studien är en av de allra första i sitt slag då den har statistisk styrka att visa om EKG-utredning efter stroke/TIA kan påverka prognosen.
  • Randomised comparison between standard and extended EKG investi gati on aft erstroke or TIA for the detecti on of atrial fi brillati on and stroke preventi on - AFSPICE
    ALF
    1 January 2024 - 31 December 2025
  • AF-SPICE - randomiserad jämförelse mellan EKG-utredningar eft er stroke/TIA
    Strokefonden
    1 January 2024 - 31 December 2025

Employments

  • Professor/Senior Consultant, Cardiology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2024-

Supervision

Thesis evaluation

  • Loreta Skrebelyte Strøm, Opponent, Department of Cardiology, Akershus University Hospital (AHUS), Faculty of Medicine, University of Oslo, Norway, PREDICTION AND DETECTION OF OCCULT ATRIAL FIBRILLATION IN PATIENTS AFTER ACUTE CRYPTOGENIC STROKE AND TRANSIENT ISCHEMIC ATTACK, 2024
  • Marita Knudsen Pope, Opponent, Department of Cardiology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Characteristics, treatment, and outcomes of patients newly diagnosed with atrial fibrillation -Insights from the GARFIELD-AF registry, 2024
  • Isabella Kharraziha, Opponent, Department of Clinical Sciences Malmö, Lund University, Novel diagnostic methods and potential treatments in cardiovascular autonomic dysfunction, 2024
  • Ole-Christian Rutherford, Opponent, Institute of Clinical Medicine, University of Oslo, Effectiveness and safety of oral anticoagulants for atrial fibrillation in the era of NOACs: Studies using Norwegian nationwide registries., 2022
  • Ekrem Yasa, Opponent, Department of Clinical Sciences, Malmö, Lund University, Cardiovascular Dysautonomia in older adults Aetiology, Diagnosis and Health related consequences, 2022

News from KI

Events from KI